• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by 23andMe Holding Co.

    10/21/24 6:44:49 PM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ME alert in real time by email
    SC 13G/A 1 d631579dsc13ga.htm SC 13G/A SC 13G/A

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    (Rule 13d-102)

    Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and

    Amendments Thereto Filed Pursuant to § 240.13d-2

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    23andMe Holding Co.

    (Name of Issuer)

    Class A Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

    90138Q306**

    (CUSIP Number)

    September 30, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    **

    This CUSIP number applies to the Issuer’s Class A Common Stock.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


     1   

     NAME OF REPORTING PERSON

     

     SEQUOIA CAPITAL GROWTH FUND III, L.P. (“SEQUOIA CAPITAL GROWTH FUND III”)

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     DELAWARE

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     181,716, of which 181,716 are Class B shares

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     181,716, of which 181,716 are Class B shares

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     181,716

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     1.0%1

    12  

     TYPE OF REPORTING PERSON

     

     PN

     

    1

    Based on a total of 17,514,628 shares of Class A Common Stock outstanding as of October 16, 2024, as reported in the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 16, 2024.


     1   

     NAME OF REPORTING PERSON

     

     SEQUOIA CAPITAL U.S. GROWTH FUND VII, L.P. (“SEQUOIA CAPITAL U.S. GROWTH FUND VII”)

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     CAYMAN ISLANDS

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     306,783, of which 306,783 are Class B shares

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     306,783, of which 306,783 are Class B shares

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     306,783

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     1.7%1

    12  

     TYPE OF REPORTING PERSON

     

     PN

     

    1

    Based on a total of 17,514,628 shares of Class A Common Stock outstanding as of October 16, 2024, as reported in the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 16, 2024.


     1   

     NAME OF REPORTING PERSON

     

    SEQUOIA CAPITAL U.S. GROWTH VII PRINCIPALS FUND, L.P. (“SEQUOIA CAPITAL U.S. GROWTH VII PRINCIPALS FUND”)

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     CAYMAN ISLANDS

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     25,235, of which 25,235 are Class B shares

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     25,235, of which 25,235 are Class B shares

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     25,235

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     0.1%1

    12  

     TYPE OF REPORTING PERSON

     

     PN

     

    1

    Based on a total of 17,514,628 shares of Class A Common Stock outstanding as of October 16, 2024, as reported in the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 16, 2024.


     1   

     NAME OF REPORTING PERSON

     

     SEQUOIA CAPITAL U.S. GROWTH FUND VIII, L.P. (“SEQUOIA CAPITAL U.S. GROWTH FUND VIII”)

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     CAYMAN ISLANDS

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     190,917, of which 190,917 are Class B shares

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     190,917, of which 190,917 are Class B shares

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     190,917

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     1.1%1

    12  

     TYPE OF REPORTING PERSON

     

     PN

     

    1

    Based on a total of 17,514,628 shares of Class A Common Stock outstanding as of October 16, 2024, as reported in the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 16, 2024.


     1   

     NAME OF REPORTING PERSON

     

     SEQUOIA CAPITAL GLOBAL GROWTH FUND II, L.P. (“SEQUOIA CAPITAL GLOBAL GROWTH FUND II”)

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     CAYMAN ISLANDS

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     183,516, of which 183,516 are Class B shares

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     183,516, of which 183,516 are Class B shares

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     183,516

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     1.0%1

    12  

     TYPE OF REPORTING PERSON

     

     PN

     

    1

    Based on a total of 17,514,628 shares of Class A Common Stock outstanding as of October 16, 2024, as reported in the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 16, 2024.


     1   

     NAME OF REPORTING PERSON

     

    SEQUOIA CAPITAL GLOBAL GROWTH II PRINCIPALS FUND, L.P. (“SEQUOIA CAPITAL GLOBAL GROWTH II PRINCIPALS FUND”)

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     CAYMAN ISLANDS

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     2,758, of which 2,758 are Class B shares

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     2,758, of which 2,758 are Class B shares

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     2,758

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     Less than 0.1%1

    12  

     TYPE OF REPORTING PERSON

     

     PN

     

    1

    Based on a total of 17,514,628 shares of Class A Common Stock outstanding as of October 16, 2024, as reported in the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 16, 2024.


     1   

     NAME OF REPORTING PERSON

     

     SCGF III MANAGEMENT, LLC (“SCGF III MANAGEMENT”)

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     DELAWARE

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

    181,716, of which 181,716 are Class B shares directly owned by SEQUOIA CAPITAL GROWTH FUND III. The general partner of SEQUOIA CAPITAL GROWTH FUND III is SCGF III MANAGEMENT.

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

    181,716, of which 181,716 are Class B shares directly owned by SEQUOIA CAPITAL GROWTH FUND III. The general partner of SEQUOIA CAPITAL GROWTH FUND III is SCGF III MANAGEMENT.

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     181,716

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     1.0%1

    12  

     TYPE OF REPORTING PERSON

     

     OO

     

    1

    Based on a total of 17,514,628 shares of Class A Common Stock outstanding as of October 16, 2024, as reported in the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 16, 2024.


     1   

     NAME OF REPORTING PERSON

     

     SC U.S. GROWTH VII MANAGEMENT, L.P. (“SC U.S. GROWTH VII MANAGEMENT”)

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     CAYMAN ISLANDS

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

    332,018, of which 306,783 are Class B shares directly owned by SEQUOIA CAPITAL U.S. GROWTH FUND VII and 25,235 are Class B shares directly owned by SEQUOIA CAPITAL U.S. GROWTH VII PRINCIPALS FUND. The General Partner of each of SEQUOIA CAPITAL U.S. GROWTH FUND VII and SEQUOIA CAPITAL U.S. GROWTH FUND VII PRINCIPALS FUND is SC U.S. GROWTH VII MANAGEMENT.

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

    332,018, of which 306,783 are Class B shares directly owned by SEQUOIA CAPITAL U.S. GROWTH FUND VII and 25,235 are Class B shares directly owned by SEQUOIA CAPITAL U.S. GROWTH VII PRINCIPALS FUND. The General Partner of each of SEQUOIA CAPITAL U.S. GROWTH FUND VII and SEQUOIA CAPITAL U.S. GROWTH FUND VII PRINCIPALS FUND is SC U.S. GROWTH VII MANAGEMENT.

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     332,018

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     1.9%1

    12  

     TYPE OF REPORTING PERSON

     

     PN

     

    1

    Based on a total of 17,514,628 shares of Class A Common Stock outstanding as of October 16, 2024, as reported in the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 16, 2024.


     1   

     NAME OF REPORTING PERSON

     

     SC U.S. GROWTH VIII MANAGEMENT, L.P. (“SC U.S. GROWTH VIII MANAGEMENT”)

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     CAYMAN ISLANDS

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

     SOLE VOTING POWER

     

     0

       6   

     SHARED VOTING POWER

     

    190,917, of which 190,917 are Class B shares directly owned by SEQUOIA CAPITAL U.S. GROWTH FUND VIII. The General Partner of SEQUOIA CAPITAL U.S. GROWTH FUND VIII is SC U.S. GROWTH VIII MANAGEMENT.

       7   

     SOLE DISPOSITIVE POWER

     

     0

       8   

     SHARED DISPOSITIVE POWER

     

    190,917, of which 190,917 are Class B shares directly owned by SEQUOIA CAPITAL U.S. GROWTH FUND VIII. The General Partner of SEQUOIA CAPITAL U.S. GROWTH FUND VIII is SC U.S. GROWTH VIII MANAGEMENT.

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     190,917

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     1.1%1

    12  

     TYPE OF REPORTING PERSON

     

     PN

     

    1

    Based on a total of 17,514,628 shares of Class A Common Stock outstanding as of October 16, 2024, as reported in the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 16, 2024.


     1   

     NAME OF REPORTING PERSON

     

     SC GLOBAL GROWTH II MANAGEMENT, L.P. (“SC GLOBAL GROWTH II MANAGEMENT”)

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     CAYMAN ISLANDS

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

     SOLE VOTING POWER

     

     0

       6   

     SHARED VOTING POWER

     

    186,274 shares, of which 183,516 are Class B shares directly owned by SEQUOIA CAPITAL GLOBAL GROWTH FUND II and 2,758 are Class B shares directly owned by SEQUOIA CAPITAL GLOBAL GROWTH II PRINCIPALS FUND. The General Partner of each of SEQUOIA CAPITAL GLOBAL GROWTH FUND II and SEQUOIA CAPITAL GLOBAL GROWTH FUND II PRINCIPALS FUND is SC GLOBAL GROWTH II MANAGEMENT.

       7   

     SOLE DISPOSITIVE POWER

     

     0

       8   

     SHARED DISPOSITIVE POWER

     

    186,274 shares, of which 183,516 are Class B shares directly owned by SEQUOIA CAPITAL GLOBAL GROWTH FUND II and 2,758 are Class B shares directly owned by SEQUOIA CAPITAL GLOBAL GROWTH II PRINCIPALS FUND. The General Partner of each of SEQUOIA CAPITAL GLOBAL GROWTH FUND II and SEQUOIA CAPITAL GLOBAL GROWTH FUND II PRINCIPALS FUND is SC GLOBAL GROWTH II MANAGEMENT.

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     186,274

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     1.1%1

    12  

     TYPE OF REPORTING PERSON

     

     PN

     

    1

    Based on a total of 17,514,628 shares of Class A Common Stock outstanding as of October 16, 2024, as reported in the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 16, 2024.


     1   

     NAME OF REPORTING PERSON

     

     SC US (TTGP), LTD. (“SC US (TTGP)”)

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     CAYMAN ISLANDS

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

     SOLE VOTING POWER

     

     0

       6   

     SHARED VOTING POWER

     

    709,209 shares, of which 306,783 are Class B shares directly owned by SEQUOIA CAPITAL U.S. GROWTH FUND VII, 25,235 are Class B shares directly owned by SEQUOIA CAPITAL U.S. GROWTH VII PRINCIPALS FUND, 190,917 are Class B shares directly owned by SEQUOIA CAPITAL U.S. GROWTH FUND VIII, 183,516 are Class B shares directly owned by SEQUOIA CAPITAL GLOBAL GROWTH FUND II and 2,758 are Class B shares directly owned by SEQUOIA CAPITAL GLOBAL GROWTH II PRINCIPALS FUND. The General Partner of each of SEQUOIA CAPITAL U.S. GROWTH FUND VII and SEQUOIA CAPITAL U.S. GROWTH FUND VII PRINCIPALS FUND is SC U.S. GROWTH VII MANAGEMENT. The General Partner of SEQUOIA CAPITAL U.S. GROWTH FUND VIII is SC U.S. GROWTH VIII MANAGEMENT. The General Partner of each of SEQUOIA CAPITAL GLOBAL GROWTH FUND II and SEQUOIA CAPITAL GLOBAL GROWTH FUND II PRINCIPALS FUND is SC GLOBAL GROWTH II MANAGEMENT. SC US (TTGP) is the General Partner of each of SC U.S. GROWTH VII MANAGEMENT, SC U.S. GROWTH VIII MANAGEMENT and SC GLOBAL GROWTH II MANAGEMENT.

       7   

     SOLE DISPOSITIVE POWER

     

     0

       8   

     SHARED DISPOSITIVE POWER

     

    709,209 shares, of which 306,783 are Class B shares directly owned by SEQUOIA CAPITAL U.S. GROWTH FUND VII, 25,235 are Class B shares directly owned by SEQUOIA CAPITAL U.S. GROWTH VII PRINCIPALS FUND, 190,917 are Class B shares directly owned by SEQUOIA CAPITAL U.S. GROWTH FUND VIII, 183,516 are Class B shares directly owned by SEQUOIA CAPITAL GLOBAL GROWTH FUND II and 2,758 are Class B shares directly owned by SEQUOIA CAPITAL GLOBAL GROWTH II PRINCIPALS FUND. The General Partner of each of SEQUOIA CAPITAL U.S. GROWTH FUND VII and SEQUOIA CAPITAL U.S. GROWTH FUND VII PRINCIPALS FUND is SC U.S. GROWTH VII MANAGEMENT. The General Partner of SEQUOIA CAPITAL U.S. GROWTH FUND VIII is SC U.S. GROWTH VIII MANAGEMENT. The General Partner of each of SEQUOIA CAPITAL GLOBAL GROWTH FUND II and SEQUOIA CAPITAL GLOBAL GROWTH FUND II PRINCIPALS FUND is SC GLOBAL GROWTH II MANAGEMENT. SC US (TTGP) is the General Partner of each of SC U.S. GROWTH VII MANAGEMENT, SC U.S. GROWTH VIII MANAGEMENT and SC GLOBAL GROWTH II MANAGEMENT.

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     709,209

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     3.9%1

    12  

     TYPE OF REPORTING PERSON

     

     PN

     

    1

    Based on a total of 17,514,628 shares of Class A Common Stock outstanding as of October 16, 2024, as reported in the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 16, 2024.


     1   

     NAME OF REPORTING PERSON

     

     DOUGLAS LEONE (“DL”)

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     USA

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     33,846

       6  

     SHARED VOTING POWER

     

    186,274 shares, of which 183,516 are Class B shares directly owned by SEQUOIA CAPITAL GLOBAL GROWTH FUND II and 2,758 are Class B shares directly owned by SEQUOIA CAPITAL GLOBAL GROWTH II PRINCIPALS FUND. The General Partner of each of SEQUOIA CAPITAL GLOBAL GROWTH FUND II and SEQUOIA CAPITAL GLOBAL GROWTH FUND II PRINCIPALS FUND is SC GLOBAL GROWTH II MANAGEMENT. SC US (TTGP) is the General Partner of SC GLOBAL GROWTH II MANAGEMENT. The directors and stockholders of SC US (TTGP) who exercise voting and investment discretion with respect to the shares held by SEQUOIA CAPITAL GLOBAL GROWTH FUND II and SEQUOIA CAPITAL GLOBAL GROWTH II PRINCIPALS FUND are Messrs. DL and RB.

       7  

     SOLE DISPOSITIVE POWER

     

     33,846

       8  

     SHARED DISPOSITIVE POWER

     

    186,274 shares, of which 183,516 are Class B shares directly owned by SEQUOIA CAPITAL GLOBAL GROWTH FUND II and 2,758 are Class B shares directly owned by SEQUOIA CAPITAL GLOBAL GROWTH II PRINCIPALS FUND. The General Partner of each of SEQUOIA CAPITAL GLOBAL GROWTH FUND II and SEQUOIA CAPITAL GLOBAL GROWTH FUND II PRINCIPALS FUND is SC GLOBAL GROWTH II MANAGEMENT. SC US (TTGP) is the General Partner of SC GLOBAL GROWTH II MANAGEMENT. The directors and stockholders of SC US (TTGP) who exercise voting and investment discretion with respect to the shares held by SEQUOIA CAPITAL GLOBAL GROWTH FUND II and SEQUOIA CAPITAL GLOBAL GROWTH II PRINCIPALS FUND are Messrs. DL and RB.

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     220,120

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     1.2%1

    12  

     TYPE OF REPORTING PERSON

     

     IN

     

    1

    Based on a total of 17,514,628 shares of Class A Common Stock outstanding as of October 16, 2024, as reported in the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 16, 2024.


     1   

     NAME OF REPORTING PERSON

     

     ROELOF BOTHA (“RB”)

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     USA

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     55,385

       6  

     SHARED VOTING POWER

     

    186,274 shares, of which 183,516 are Class B shares directly owned by SEQUOIA CAPITAL GLOBAL GROWTH FUND II and 2,758 are Class B shares directly owned by SEQUOIA CAPITAL GLOBAL GROWTH II PRINCIPALS FUND. The General Partner of each of SEQUOIA CAPITAL GLOBAL GROWTH FUND II and SEQUOIA CAPITAL GLOBAL GROWTH FUND II PRINCIPALS FUND is SC GLOBAL GROWTH II MANAGEMENT. SC US (TTGP) is the General Partner of SC GLOBAL GROWTH II MANAGEMENT. The directors and stockholders of SC US (TTGP) who exercise voting and investment discretion with respect to the shares held by SEQUOIA CAPITAL GLOBAL GROWTH FUND II and SEQUOIA CAPITAL GLOBAL GROWTH II PRINCIPALS FUND are Messrs. DL and RB.

       7  

     SOLE DISPOSITIVE POWER

     

     55,385

       8  

     SHARED DISPOSITIVE POWER

     

    186,274 shares, of which 183,516 are Class B shares directly owned by SEQUOIA CAPITAL GLOBAL GROWTH FUND II and 2,758 are Class B shares directly owned by SEQUOIA CAPITAL GLOBAL GROWTH II PRINCIPALS FUND. The General Partner of each of SEQUOIA CAPITAL GLOBAL GROWTH FUND II and SEQUOIA CAPITAL GLOBAL GROWTH FUND II PRINCIPALS FUND is SC GLOBAL GROWTH II MANAGEMENT. SC US (TTGP) is the General Partner of SC GLOBAL GROWTH II MANAGEMENT. The directors and stockholders of SC US (TTGP) who exercise voting and investment discretion with respect to the shares held by SEQUOIA CAPITAL GLOBAL GROWTH FUND II and SEQUOIA CAPITAL GLOBAL GROWTH II PRINCIPALS FUND are Messrs. DL and RB.

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     241,659

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     1.4%1

    12  

     TYPE OF REPORTING PERSON

     

     IN

     

    1

    Based on a total of 17,514,628 shares of Class A Common Stock outstanding as of October 16, 2024, as reported in the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 16, 2024.


    ITEM 1.

    (a) Name of Issuer:

    23andMe Holding Co.

    (b) Address of Issuer’s Principal Executive Offices:

    223 N. Mathilda Avenue

    Sunnyvale, California 94086

     

    ITEM 2.

    (a) Name of Persons Filing:

    Sequoia Capital Growth Fund III, L.P.

    Sequoia Capital U.S. Growth Fund VII, L.P.

    Sequoia Capital U.S. Growth VII Principals Fund, L.P.

    Sequoia Capital U.S. Growth Fund VIII, L.P.

    Sequoia Capital Global Growth Fund II, L.P.

    Sequoia Capital Global Growth II Principals Fund, L.P.

    SCGF III Management, L.P.

    SC U.S. Growth VII Management, L.P.

    SC U.S. Growth VIII Management, L.P.

    SC Global Growth II Management, L.P.

    SC US (TTPG), Ltd.

    Douglas Leone

    Roelof Botha

    The general partner of SEQUOIA CAPITAL GROWTH FUND III is SCGF III MANAGEMENT.

    The General Partner of each of SEQUOIA CAPITAL U.S. GROWTH FUND VII and SEQUOIA CAPITAL U.S. GROWTH FUND VII PRINCIPALS FUND is SC U.S. GROWTH VII MANAGEMENT. SC US (TTGP) is the General Partner of SC U.S. GROWTH VII MANAGEMENT.

    The General Partner of SEQUOIA CAPITAL U.S. GROWTH FUND VIII is SC U.S. GROWTH VIII MANAGEMENT. SC US (TTGP) is the General Partner of SC U.S. GROWTH VIII MANAGEMENT.

    The General Partner of each of SEQUOIA CAPITAL GLOBAL GROWTH FUND II and SEQUOIA CAPITAL GLOBAL GROWTH FUND II PRINCIPALS FUND is SC GLOBAL GROWTH II MANAGEMENT. SC US (TTGP) is the General Partner of SC GLOBAL GROWTH II MANAGEMENT. The directors and stockholders of SC US (TTGP) who exercise voting and investment discretion with respect to the shares held by SEQUOIA CAPITAL GLOBAL GROWTH FUND II and SEQUOIA CAPITAL GLOBAL GROWTH II PRINCIPALS FUND are Messrs. DL and RB.

    (b) Address of Principal Business Office or, if none, Residence:

    2800 Sand Hill Road, Suite 101

    Menlo Park, CA 94025

    (c) Citizenship:


    SEQUOIA CAPITAL U.S. GROWTH FUND VII, SEQUOIA CAPITAL U.S. GROWTH FUND VII PRINCIPALS FUND, SEQUOIA CAPITAL U.S. GROWTH FUND VIII, SEQUOIA CAPITAL GLOBAL GROWTH FUND II, L.P., SEQUOIA CAPITAL GLOBAL GROWTH II PRINCIPALS FUND, L.P., SC U.S. GROWTH VII MANAGEMENT, L.P., SC U.S. GROWTH VIII MANAGEMENT, L.P., SC GLOBAL GROWTH II MANAGEMENT, L.P., SC US (TTGP), LTD., Cayman Islands

    SEQUOIA CAPITAL GROWTH FUND III, SCGF III MANAGEMENT: Delaware

    DL, RB: USA

    (d) CUSIP Number:

    90138Q306

    ITEM 3.

    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

    NOT APPLICABLE

     

    ITEM 4.

    OWNERSHIP

    SEE ROWS 5 THROUGH 11 OF COVER PAGES

     

    ITEM 5.

    OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒.

     

    ITEM 6.

    OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON

    NOT APPLICABLE

     

    ITEM 7.

    IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.

    NOT APPLICABLE

     

    ITEM 8.

    IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.

    NOT APPLICABLE

     

    ITEM 9.

    NOTICE OF DISSOLUTION OF GROUP.

    NOT APPLICABLE

     

    ITEM 10.

    CERTIFICATION

    NOT APPLICABLE


    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Dated: October 21, 2024

     

    Sequoia Capital Growth Fund III, L.P.

    By: SCGF III Management, LLC

    its General Partner

    By:  

    /s/ Jung Yeon Son

      Jung Yeon Son, by power of attorney for Roelof Botha, Director

    Sequoia Capital U.S. Growth Fund VII, L.P.

     

    By: SC U.S. Growth VII Management, L.P.

    its General Partner

     

    By: SC US (TTGP), Ltd.

    its General Partner

    By:  

    /s/ Jung Yeon Son

      Jung Yeon Son, by power of attorney for Roelof Botha, Director

    Sequoia Capital U.S. Growth VII Principals Fund, L.P.

     

    By: SC U.S. Growth VII Management, L.P.

    its General Partner

     

    By: SC US (TTGP), Ltd.

    its General Partner

    By:  

    /s/ Jung Yeon Son

      Jung Yeon Son, by power of attorney for Roelof Botha, Director

    Sequoia Capital U.S. Growth Fund VIII, L.P.

     

    By: SC U.S. Growth VIII Management, L.P.

    its General Partner

     

    By: SC US (TTGP), Ltd.

    its General Partner

    By:  

    /s/ Jung Yeon Son

      Jung Yeon Son, by power of attorney for Roelof Botha, Director


    Sequoia Capital Global Growth Fund II, L.P.

    By: SC Global Growth II Management, L.P.

    its General Partner

    By: SC US (TTGP), Ltd.

    its General Partner

    By:  

    /s/ Jung Yeon Son

      Jung Yeon Son, by power of attorney for Roelof Botha, Director

    Sequoia Capital Global Growth II Principals Fund, L.P.

     

    By: SC Global Growth II Management, L.P.

    its General Partner

     

    By: SC US (TTGP), Ltd.

    its General Partner

    By:  

    /s/ Jung Yeon Son

      Jung Yeon Son, by power of attorney for Roelof Botha, Director
    SCGF III Management, LLC
    By:  

    /s/ Jung Yeon Son

      Jung Yeon Son, by power of attorney for Roelof Botha, Director

    SC U.S. Growth VII Management, L.P.

     

    By: SC US (TTGP), Ltd.

    its General Partner

    By:  

    /s/ Jung Yeon Son

      Jung Yeon Son, by power of attorney for Roelof Botha, Director

    SC U.S. Growth VIII Management, L.P.

     

    By: SC US (TTGP), Ltd.

    its General Partner

    By:  

    /s/ Jung Yeon Son

      Jung Yeon Son, by power of attorney for Roelof Botha, Director


    SC Global Growth II Management, L.P.

     

    By: SC US (TTGP), Ltd.

    its General Partner

    By:  

    /s/ Jung Yeon Son

      Jung Yeon Son, by power of attorney for Roelof Botha, Director
    SC US (TTGP), Ltd.
    By:  

    /s/ Jung Yeon Son

      Jung Yeon Son, by power of attorney for Roelof Botha, Director
    Douglas Leone
    By:  

    /s/ Jung Yeon Son

      Jung Yeon Son, by power of attorney for Douglas Leone
    Roelof Botha
    By:  

    /s/ Jung Yeon Son

     

    Jung Yeon Son, by power of attorney for

    Roelof Botha

    Get the next $ME alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ME

    DatePrice TargetRatingAnalyst
    11/29/2022$7.00Buy
    Berenberg
    9/22/2022$6.00Outperform
    Cowen
    2/11/2022$14.00 → $11.00Outperform
    Credit Suisse
    12/20/2021$13.00 → $9.00Neutral
    Citigroup
    11/15/2021$12.00 → $13.00Buy → Neutral
    Citigroup
    11/11/2021$13.00 → $14.00Outperform
    Credit Suisse
    8/17/2021$13.00Outperform
    Credit Suisse
    7/12/2021$14.00Buy
    Citigroup
    More analyst ratings

    $ME
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Kvarda Matthew

      3 - 23andMe Holding Co. (0001804591) (Issuer)

      3/26/25 4:38:00 PM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Walper Thomas B.

      3 - 23andMe Holding Co. (0001804591) (Issuer)

      3/26/25 4:35:46 PM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial & Actng Ofcr Selsavage Joseph Anthony covered exercise/tax liability with 5,654 shares, decreasing direct ownership by 6% to 96,468 units (SEC Form 4)

      4 - 23andMe Holding Co. (0001804591) (Issuer)

      2/21/25 5:05:56 PM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ME
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by 23andMe Holding Co.

      SC 13D/A - 23andMe Holding Co. (0001804591) (Subject)

      11/15/24 4:48:20 PM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by 23andMe Holding Co.

      SC 13D/A - 23andMe Holding Co. (0001804591) (Subject)

      11/15/24 4:20:24 PM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by 23andMe Holding Co.

      SC 13G - 23andMe Holding Co. (0001804591) (Subject)

      11/13/24 6:00:29 AM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ME
    Financials

    Live finance-specific insights

    See more
    • 23andMe Reports Second Quarter Fiscal Year 2025 Financial Results

      SUNNYVALE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME), a leading human genetics and preventive health company, reported its financial results for the second quarter of fiscal year 2025 (FY25), which ended September 30, 2024. Key Results: Improved GAAP Net Loss by 21% and Adjusted EBITDA by 26% for the same period in the prior year (see important additional information below).The 23andMe comprehensive Total Health longevity service is now available to all customers, combining whole exome genetic sequencing with bi-annual lab tests for 55+ key blood biomarkers, and expert clinicians trained in genetics-informed preventive care and health action p

      11/12/24 7:30:00 AM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CORRECTION - 23andMe to Report Q2 FY2025 Financial Results

      SUNNYVALE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- An earlier release under the same headline should have noted 23andMe Holding Co. (NASDAQ:ME) (23andMe) will report financial results for the second quarter of fiscal year 2025 (FY2025) prior to the market opening on Tuesday, November 12, 2024 (the prior release incorrectly stated the results would be reported after the market closes). The Company will webcast a conference call at 8:00 a.m. Eastern Time on that date to discuss the quarter's results and report on business progress. The webcast can be accessed on the day of the event at this link. A webcast replay will be available at the same address following the event. In addition, 23

      11/7/24 5:54:12 PM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 23andMe to Report Q2 FY2025 Financial Results

      SUNNYVALE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) (23andMe), a leading human genetics and biopharmaceutical company, announced today that it will report financial results for the second quarter of fiscal year 2025 (FY2025) after the market closes on Tuesday, November 12, 2024. The Company will webcast a conference call at 4:30 p.m. Eastern Time on that date to discuss the quarter's results and report on business progress. The webcast can be accessed on the day of the event at this link. A webcast replay will be available at the same address following the event. In addition, 23andMe will use the Say Technologies platform to allow retail and institutional

      11/7/24 7:30:00 AM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ME
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • 23andMe Confirms All Potential Buyers Must Agree to Comply With Privacy Policy and Applicable Law

      SAN FRANCISCO, March 26, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. ("23andMe" or the "Company") (NASDAQ:ME), a leading human genetics and biotechnology company, today announced that it has received approvals from the U.S. Bankruptcy Court for the Eastern District of Missouri (the "Court") for its "first day" motions related to 23andMe's voluntary Chapter 11 petitions filed March 23, 2025, including authorization to pay employee wages and benefits and compensate certain vendors and suppliers in the ordinary course for goods and services provided and to enter into the binding term sheet for a $35 million debtor-in-possession financing facility from JMB Capital Partners (the "DIP Facility"

      3/26/25 6:57:42 PM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 23andMe Initiates Voluntary Chapter 11 Process to Maximize Stakeholder Value Through Court-Supervised Sale Process

      Intends to use Proceedings to Conduct a Value-Maximizing Sale Process and Resolve Liabilities Company Expects to Continue Business Operations in the Ordinary Course During Proceedings; Secures Commitment for Approximately $35 Million in DIP Financing to Support Ongoing Operations No Changes to Customer Data Management and Access; Company Remains Committed to Transparency Around Customer Data Privacy; Any Buyer will be Required to Comply with Applicable Law with Respect to Treatment of Customer Data Company Announces Board and Leadership Changes to Support Restructuring and Sale Process SAN FRANCISCO, March 23, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. ("23andMe" or the "Company") (

      3/23/25 11:08:03 PM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 23andMe Launches New Homocysteine (MTHFR-Related) Genetic Report and Accompanying Lab Test

      SAN FRANCISCO, March 21, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME), a leading human genetics company with a mission to help people access, understand, and benefit from the human genome, today released a new report on the genetics of homocysteine levels for 23andMe+ Premium members, as well as a blood test for next steps in further understanding said levels for an additional fee. One of the top 23andMe customer requested reports, it informs users if they are at a higher likelihood of developing slightly elevated homocysteine levels along with actionable lifestyle factors that can reduce their chances. Homocysteine is an amino acid that plays a key role in important process

      3/21/25 7:30:00 AM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ME
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Berenberg initiated coverage on 23andMe with a new price target

      Berenberg initiated coverage of 23andMe with a rating of Buy and set a new price target of $7.00

      11/29/22 7:24:54 AM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cowen initiated coverage on 23andMe with a new price target

      Cowen initiated coverage of 23andMe with a rating of Outperform and set a new price target of $6.00

      9/22/22 7:20:18 AM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Credit Suisse reiterated coverage on 23andMe Holding with a new price target

      Credit Suisse reiterated coverage of 23andMe Holding with a rating of Outperform and set a new price target of $11.00 from $14.00 previously

      2/11/22 8:14:04 AM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ME
    SEC Filings

    See more

    $ME
    Leadership Updates

    Live Leadership Updates

    See more
    • SEC Form 8-K filed by 23andMe Holding Co.

      8-K - 23andMe Holding Co. (0001804591) (Filer)

      3/28/25 4:09:11 PM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 23andMe Holding Co. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - 23andMe Holding Co. (0001804591) (Filer)

      3/24/25 6:23:28 AM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by 23andMe Holding Co.

      10-Q - 23andMe Holding Co. (0001804591) (Filer)

      2/6/25 4:27:52 PM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 23andMe Appoints Three New Independent Directors to Board

      SUNNYVALE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) (the "Company" or "23andMe"), a leading human genetics and preventive health company, today announced the appointments of Andre Fernandez, Jim Frankola, and Mark Jensen, three accomplished and experienced executives, as independent members of the Company's Board of Directors (the "Board"), effective on October 28, 2024. Each of Mr. Fernandez, Mr. Frankola, and Mr. Jensen have been appointed to serve as members of the Board's Audit Committee and Compensation Committee, with Mr. Fernandez serving as the Chair of the Audit Committee and Mr. Jensen serving as the Chair of the Compensation Committee. In additio

      10/29/24 7:30:00 AM ET
      $ANSS
      $CDLX
      $LSCC
      $ME
      Computer Software: Prepackaged Software
      Technology
      Computer Software: Programming Data Processing
      Semiconductors
    • Madryn Asset Management, a Top Shareholder of SomaLogic, Issues Letter Regarding Opposition to the Company's Proposed Merger with Standard BioTools

      Files Preliminary Proxy Statement to Solicit Shareholders to Oppose the Merger Intends to Vote AGAINST the Conflict-Plagued and Excessively Dilutive Transaction, Which Stands to Unduly Benefit Certain Investors and Standard BioTools at the Expense of SomaLogic's Shareholders Notes the Current Premium for SomaLogic Shareholders, Based on the Deal's Exchange Ratio and Standard BioTools' Trading Price, is Only ~4.3% Underscores That SomaLogic Has Superior Alternatives to a Flawed Combination, Including a Standalone Path Leveraging its Considerable Cash Position and Strong Balance Sheet Madryn Asset Management, LP (collectively with its affiliates, "Madryn"), a holder of approximately 4

      12/12/23 5:31:00 PM ET
      $EXAS
      $ILMN
      $LAB
      $ME
      Medical Specialities
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Reza Afkhami Joins 23andMe as Chief Corporate Development Officer

      SOUTH SAN FRANCISCO, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) ("23andMe"), a leading human genetics and biopharmaceutical company, today announced the appointment of Reza Afkhami as its Chief Corporate Development Officer overseeing corporate development efforts across its therapeutics, research services and consumer groups. Afkhami will be responsible for spearheading and driving a wide range of industry collaborations for the Company. 23andMe Therapeutics has a pipeline of genetically validated discovery and clinical programs, which it intends to advance through collaborations with pharmaceutical companies. Furthermore, 23andMe hopes to help the pharmac

      5/8/23 7:00:00 AM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care